Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-03-25T06:44:22.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-03-10T23:28:33.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.6%
    Check dated 2025-02-24T16:15:51.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2025-02-17T12:38:38.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect new results and timelines for a clinical study, including the addition of specific dates for results posting and clarifications on eligibility criteria for participants with myelodysplastic syndrome (MDS). Additionally, there are updates on the analysis methods and outcome measures related to treatment efficacy.
    Difference
    39%
    Check dated 2025-02-10T09:00:09.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.2%
    Check dated 2025-02-03T04:44:25.000Z thumbnail image

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.